Join to View Full Profile
6230 University PkwySte 203Sarasota, FL 34240
Phone+1 941-500-3200
Dr. Neff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Guy Neff is a researcher in Sarasota, FL. He received his medical degree from Northeast Ohio Medical University and has been in practice 25 years. He is experienced in hepatology.
Education & Training
Louisiana State University School of MedicineFellowship, Gastroenterology, 1995 - 1997
Canton Medical Education Foundation/NEOMEDResidency, Internal Medicine, 1992 - 1995- Aultman Hospital/NEOMEDInternship, Transitional Year, 1992 - 1992
Northeast Ohio Medical UniversityClass of 1992
Certifications & Licensure
FL State Medical License 1997 - 2026
OH State Medical License 1993 - 2012
LA State Medical License 1995 - 2001
IA State Medical License 1996 - 2000
National Board of Physicians and Surgeons Gastroenterology- National Board of Physicians and Surgeons Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA) Start of enrollment: 2006 Sep 01
Publications & Presentations
PubMed
- 138 citationsResmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.Stephen A Harrison, Rebecca Taub, Guy W Neff, K Jean Lucas, Dominic Labriola
Nature Medicine. 2023-11-01 - 42 citationsA phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.Christopher L Bowlus, Michael R Galambos, Richard J Aspinall, Gideon M Hirschfield, David E J Jones
Journal of Hepatology. 2022-08-01 - 53 citationsA phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes.Stephen A. Harrison, Nadege Gunn, Guy W. Neff, Anita Kohli, Liping Liu
Nature Communications. 2021-09-17
Press Mentions
Echosens Observes October 2018 Liver Cancer Awareness Month: Know Your Risk for Nonalcoholic Fatty Liver Disease – A Looming National EpidemicOctober 17th, 2018- Research Points to National Epidemic of Undiagnosed Fatty Liver Disease: Florida Research Institute and Echosens Announce Results at the American College of GastroenterologyOctober 9th, 2018
NASH – A Silent Killer: 150 World Experts Sign a Global Call to Action to Promote Awareness of Deadly Liver DiseaseJune 5th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
